Comparative Pharmacology
Head-to-head clinical analysis: DEPO TESTOSTERONE versus FORTESTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO TESTOSTERONE versus FORTESTA.
DEPO-TESTOSTERONE vs FORTESTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Testosterone replacement therapy; testosterone binds to and activates androgen receptors, influencing gene transcription and protein synthesis, leading to the development of male secondary sex characteristics and maintenance of libido, muscle mass, and bone density.
50-400 mg IM every 2-4 weeks
Apply one 30 mg metered-dose transdermal system to abdomen or upper arm once daily at the same time each day.
None Documented
None Documented
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
Terminal elimination half-life is 3–4 hours; not clinically significant for once-daily transdermal administration due to sustained absorption.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); approximately 1% fecal.
Category D/X
Category C
Androgen
Androgen